"An investment in knowledge pays the best interest."


Revive Therapeutics Ltd. (RVV.V) has obtained positive results from its research program of cannabinoid-based therapies targeting liver diseases, demonstrating certain cannabinoids being effective in a liver fibrosis model and may serve as novel treatments for liver fibrogenesis.

"I am very pleased to have led and managed a unique drug discovery program involving phytocannabinoids, which has resulted in the discovery of novel compounds for the potential treatment of liver fibrosis and other liver disease indications that will be further explored," said Dr. Pritesh Kumar, scientific adviser for the company and chief executive officer of PhytoSciences Consulting LLC. "The research that was sponsored by Revive completes a critical step in advancing novel compounds as potential therapeutics for specific liver diseases. I look forward to be the first to report these findings from the research program that I led and I am excited to contribute my expertise to further validate and potentially advance these discoveries for liver diseases."

"We are very pleased with the outcome of our research program for the discovery and the validation of a number of cannabinoids for the treatment of liver fibrosis," said Craig Leon, chief executive officer of Revive. "We remain focused on building a liver disease franchise, via research and development, licensing, and strategic partnering, that will be unique to the pharmaceutical community and targeting significantly unmet medical needs in a number of liver disease indications."

The company's research program was conducted by PhytoSciences Consulting LLC, a contract research organization and led by Dr. Kumar. The research program employed an in vivo compound screening approach to investigate phytocannabinoids in a fibrosis model utilizing an in-house cell-based screening model. The cell-based ligand screening is a targeted experimental approach that involved approximately 80 phytocannabinoids. The initial screen of phytocannabinoids resulted in the identification of several promising hits, which demonstrated to be effective at preventing the activation of the cells by transforming growth factor beta (TGF-beta), thus serving as potential therapeutics for liver fibrogenesis. In the pathological process of liver fibrosis, TGF-beta plays as a master profibrogenic cytokine in promoting activation and myofibroblastic differentiation of hepatic stellate cells, a central event in liver fibrogenesis. Continuous and/or persistent TGF-beta signalling induces sustained production of the extracellular matrix components and of tissue inhibitor of metalloproteinase synthesis. Therefore, the regulation of locally activated TGF-beta levels is increasingly recognized as a therapeutic target for liver fibrogenesis. The results of the company's research efforts demonstrate that the ligands in question may serve as a novel treatment for liver fibrogenesis and warrant further investigation in animal models.